Solitary, late metastatic recurrence of renal cell carcinoma: Two extraordinary cases

Featherstone, Jonathan; Bass, Paul; Cumming, J. A.; Smart, C. J.

doi:10.1111/j.1442-2042.2006.01577.x

Cited by 22 publications

(19 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Generally, an immune cell-inhibiting mechanism is present in the microcirculatory environment of tumors (20). A trace number of cancer cells of RCC were latently present under the control of the immunological surveillance mechanism, but it may have manifested because the DLBCL tumor volume rapidly increased and inhibited immunity, and the subsequent growth of metastatic cancer cells from RCC may have been slightly rapid, unlike the slow growth previously reported (1,6,17).…”

Section: Discussionmentioning

confidence: 97%

“…The most common sites of metastasis are the lung, liver, and bones (4). Clinically evident gastrointestinal involvement of RCC, especially solitary duodenal metastasis from RCC is rare and most frequently involves the periampullary region or the duodenal bulb (5,6). According to recent report (7), of the 3637 patients diagnosed with RCC, 15 patients (0.4%) with 19 gastrointestinal lesions were identified, and duodenum involvement was 6 lesions.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Late duodenal metastasis from renal cell carcinoma with newly developed malignant lymphoma: A case report

Saito¹,

Senjo²,

Kanaya³

et al. 2018

mol clin onc

View full text Add to dashboard Cite

Abstract. Duodenal metastasis from renal cell carcinoma (RCC) is rare. The current case report presents a very rare case of late duodenal metastasis from RCC with newly developed malignant lymphoma (diffuse large B-cell lymphoma: DLBCL) at the same time. A 64-year-old man with systemic lymph nodes swelling who had undergone left nephrectomy for RCC 25 years previously, was admitted to the present hospital. Inguinal lymph node biopsy was performed, leading to a diagnosis of DLBCL. fluorine-18-fluorodeoxy-glucose ( 18 F-FDG)-positron emission tomography (PET)/computed tomography (CT) revealed multiple lymph nodes, spleen, and ileocecal lesions. CT revealed an obvious hypervascular tumor involving the duodenum/pancreatic head. The tumor was false-negative on 18 F-FDG-PET/CT. On esophagogastroduodenoscopy, the tumor was detected in the descending portion of the duodenum and was observed to be consistent with the submucosal tumor with a central ulcer, resembling those of ulcer-forming DLBCL. A biopsy was then performed carefully, and a clear cell RCC-derived metastatic cancer was diagnosed. Ileocolonoscopy revealed mucosal thickening of the terminal ileum, and led to a diagnosis of DLBCL infiltration with biopsy. To the best of the author's knowledge, this is the first case report of the coexistence of metastatic cancer from RCC and malignant lymphoma in the small intestine simultaneously. It was necessary to make a careful differential diagnosis in the imaging studies.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

Late duodenal metastasis from renal cell carcinoma with newly developed malignant lymphoma: A case report

Saito¹,

Senjo²,

Kanaya³

et al. 2018

mol clin onc

View full text Add to dashboard Cite

show abstract

“…[5,6] Long term survival rates of 21-44% have been documented following curative resection for RCC metastases at various sites. [7] Metastases from renal cell carcinoma can be diagnosed in virtually any location, but they commonly spread to the lung (75%), regional lymph nodes (60-65%), bones (20%), liver (18%), skin (8%), and central nervous system (8%). [3] The bone is the second common site of distant metastasis.…”

Section: Discussionmentioning

confidence: 99%

22-year survival following radical nephrectomy and several metastasectomies in a case of renal cell carcinoma

Yücel

Tunç

Başaran

et al. 2017

Turkish Journal of Urology

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is a common malignancy. Metastases can be seen both synchronously, at the time of diagnosis, and metachronously during follow-up. At the time of diagnosis, 23% of the patients have metastatic disease. and 25% of patients will develop metastasis during follow-up period after nephrectomy. Nearly 80% of them develop within the first 5 years. However late metastasis of RCC have been also reported within the postoperative 10 years in the literature. For metastatic lesions, if surgically feasible, metastasectomy, and targeted pharmaceutical agents have been recommended. However any randomized controlled study which aimed to determine treatment protocol in patients who develop multiple metastases has not been cited in the literature. Herein, we are presenting a case with renal cell carcinoma in whom within 22 years of follow-up after 10 years of survival multiple metastases in different organs were detected which were managed with surgical, and medical treatments. As far as we know, this case is the first patient with the longest survival whose non-pulmonary metastases had been treated with more than one surgical interventions.

show abstract

“…Excision of recurrent and metastatic lesions leads to longer survival (345) while improvements in patient care and new treatment modalities, such as administering anti-angiogenic agents, may also improve the overall survival benefits by reducing pharmacological toxicity and improving quality of life (36). Although RCC can metastasize to any site in the body, clinically evident gastrointestinal (GI) involvement is extremely rare (78), likely leading to its underdiagnosis due to its low prevalence. In addition, such cases do not receive much clinical attention since they are frequently regarded as an aspect of generalized metastatic disease.…”

Section: Introductionmentioning

confidence: 99%

Gastrointestinal Involvement of Recurrent Renal Cell Carcinoma: CT Findings and Clinicopathologic Features

et al. 2017

View full text Add to dashboard Cite

ObjectiveTo retrospectively evaluate the CT findings and clinicopathologic features in patients with gastrointestinal (GI) involvement of recurrent renal cell carcinoma (RCC).Materials and MethodsThe medical records were reviewed for 15 patients with 19 pathologically proven GI tract metastases of RCC. The CT findings were analyzed to determine the involved sites and type of involvement; lesion size, morphology, and contrast enhancement pattern; and occurrence of lymphadenopathy, ascites and other complications.ResultsThe most common presentation was GI bleeding (66.7%). The average interval between nephrectomy and the detection of GI involvement was 30.4 ± 37.4 months. GI lesions were most commonly found in the ileum (36.8%) and duodenum (31.6%). A distant metastasis (80%) was more common than a direct invasion from metastatic lesions. The mean lesion size was 34.1 ± 15.0 mm. Intraluminal polypoid masses (63.2%) with hyperenhancement (78.9%) and heterogeneous enhancement (63.2%) were the most common findings. No patients had regional lymphadenopathy. Complications occurred in four patients, with one each of bowel obstruction, intussusception, bile duct dilatation, and pancreatic duct dilatation.ConclusionGI involvement of recurrent RCC could be included in the differential diagnosis of patients with heterogeneous, hyperenhanced intraluminal polypoid masses in the small bowel on CT scans along with a relative paucity of lymphadenopathy.

show abstract

Solitary, late metastatic recurrence of renal cell carcinoma: Two extraordinary cases

Cited by 22 publications

References 12 publications

Late duodenal metastasis from renal cell carcinoma with newly developed malignant lymphoma: A case report

Late duodenal metastasis from renal cell carcinoma with newly developed malignant lymphoma: A case report

22-year survival following radical nephrectomy and several metastasectomies in a case of renal cell carcinoma

Gastrointestinal Involvement of Recurrent Renal Cell Carcinoma: CT Findings and Clinicopathologic Features

Contact Info

Product

Resources

About